About GondolaBio
GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.
Who You Are
GondolaBio’s Asset Acquisition team is seeking an Associate/Sr. Associate to help us define our new programs. We are looking for ambitious scientists who’d like to contribute at the intersection of science and business. Our team is responsible for finding, evaluating, and determining which therapeutic ideas GondolaBio will pursue, with an emphasis on evaluation of the scientific rationale behind therapeutic strategies. The team works closely with GondolaBio’s Investment Committee, which is composed of veteran drug developers and renowned academic scientists. Across the BridgeBio ecosystem, we have spearheaded partnerships with academic and industry groups to create, fund, and operate >30 new drug development programs. As a key member of the team, this position will help set the culture and business development of the company and will be the face of the organization.
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.